This Guy Created a $10 Billion Deal! He Just Joined a New Biotech… NOW!
Could one strategic board appointment unlock billions for a biotech company? Slate Medicines, a private firm pioneering new migraine treatments, just made a game-changing move by welcoming Mark W. Hahn to its Board of Directors. Hahn’s remarkable 25-year career includes successfully navigating Verona Pharma through critical Phase 3 trials and an astonishing $10 billion acquisition by Merck. His proven expertise in guiding companies from private to public and through major commercial milestones will be instrumental as Slate strives to deliver innovative therapies to patients currently underserved. Stay ahead of groundbreaking industry news and subscribe to our channel for more exclusive insights!
Tags/Hashtags: #biotech #merck
Leave a Reply